Takeda Pharmaceuticals will be a partner I of the All-Russian Pharmaceutical Run in Yaroslavl. Representatives of the company will share their expertise in the production and launch of orphan drugs, international trends in organizing medical care for patients with rare diseases, and will also participate in a round table on the topic “Registration and launch of new drugs on the market. The social aspect and issues of state regulation ”, which will be held on June 1, 2019 in Yaroslavl.
The procedure for the withdrawal of drugs in Russia is a long, laborious and financially costly process with many stages, some of which are recognized by experts as redundant. Due to the complexities of the system, patients are not always able to receive the necessary medication on time, therefore they do not receive proper treatment or are forced to look for options abroad.
This topic will be devoted to the sixth day of the First All-Russian Pharmaceutical Run. At the round table “Registration and launch of new drugs on the market. The social aspect and issues of state regulation ”leading experts in the pharmaceutical industry will comprehensively consider the acute issues in this area.
Representatives of government agencies, pharmaceutical companies and universities will discuss the topic from the perspective of business, regulators and patients themselves, including regulating the introduction of drugs into circulation, pricing and state support, public requests and the necessary changes to increase the availability of drug therapy. The moderator will be the Director General of the Association of Russian Pharmaceutical Manufacturers Victor Dmitriev .
& nbsp; “Issues of ensuring the availability of orphan innovative drugs are acute for any drug supply system and require constant dialogue between the state and the expert community, as well as the participation of pharmaceutical manufacturers in their discussion. A number of drugs are already being produced in Russia, which opens up new possibilities in the treatment of patients with serious diseases. This is due, inter alia, to the participation of international pharmaceutical companies, which are transferring their advanced developments to Russia. Therefore, the continuous improvement of the mechanisms for introducing innovative pharmaceutical products to the market and finding the best place for them in the healthcare system are cross-cutting issues, both for the healthcare system and for the further development of the domestic pharmaceutical industry, ”I.O. CEO of Takeda Evgeny Abramov .
To participate in the Pharmaceutical Run business program, you must fill out the preliminary registration form on the website https://pharmprobeg.ru/programma/ , as well as receive confirmation from the organizers.